Department of Pathogenic Biology and Immunology, School of Basic Medical Science, Southeast University, Nanjing, China.
Cancer Gene Ther. 2010 Oct;17(10):675-83. doi: 10.1038/cgt.2010.23. Epub 2010 Jun 11.
Previous studies have indicated that the cytokine interleukin (IL)-21 may induce both innate and adaptive immune responses against tumors. The goal of this study was to evaluate a new adoptive immunotherapy strategy that combined lymphocytes from mice immunized with a murine myeloma vaccine secreting murine IL-21 (mIL-21-Sp2/0) in lymphopenic mice induced by cyclophosphamide. The data indicate that effective antitumor immunity was induced in mice receiving syngeneic murine lymphocytes from the mice immunized with the mIL-21-Sp2/0. More importantly, the efficacy against the Sp2/0 cell challenge was enhanced after the lymphocytes were activated and proliferated ex vivo before administration into the lymphopenic mice. We conclude that the adoptive transfer of tumor antigen-specific lymphocytes into mice immunized with mIL-21-Sp2/0 induced protective immune responses against myeloma challenge.
先前的研究表明细胞因子白细胞介素（IL）-21 可能诱导针对肿瘤的先天和适应性免疫反应。本研究的目的是评估一种新的过继免疫治疗策略，即将在环磷酰胺诱导的淋巴耗竭小鼠中用分泌小鼠白细胞介素（mIL）-21 的小鼠骨髓瘤疫苗免疫的小鼠的淋巴细胞与淋巴细胞联合使用。数据表明，接受来自用 mIL-21-Sp2/0 免疫的小鼠的同种异体小鼠淋巴细胞的小鼠中诱导了有效的抗肿瘤免疫。更重要的是，在将淋巴细胞在体外激活和增殖后再施用于淋巴耗竭小鼠，其对 Sp2/0 细胞的攻击的疗效得到了增强。我们得出结论，将肿瘤抗原特异性淋巴细胞过继转移到用 mIL-21-Sp2/0 免疫的小鼠中，可诱导针对骨髓瘤攻击的保护性免疫反应。
